UCB (OTCMKTS:UCBJF) Sees Strong Trading Volume – Time to Buy?

UCB SA (OTCMKTS:UCBJF) shares saw strong trading volume on Monday . 7,964 shares were traded during trading, an increase of 1,012% from the previous session’s volume of 716 shares.The stock last traded at $278.42 and had previously closed at $280.8525.

Analyst Ratings Changes

Several analysts have commented on the stock. Wolfe Research assumed coverage on shares of UCB in a research note on Monday, February 23rd. They set an “outperform” rating for the company. The Goldman Sachs Group restated a “buy” rating on shares of UCB in a research note on Monday, February 16th. Finally, Stephens restated an “overweight” rating on shares of UCB in a research note on Thursday, January 15th. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy”.

UCB Stock Up 1.3%

The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19. The firm’s fifty day moving average price is $299.95 and its two-hundred day moving average price is $295.42.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.